Back to the Top
The following message was posted to: PharmPK
Is it wise to pre-specify a no-effect boundary (e.g.,
80-125%) in a multiple ascending dose protocol for evaluating single
Want to post a follow-up message on this topic?
If this link does not work with your browser send a follow-up message to PharmPK@boomer.org with "Multiple ascending dose protocol" as the subject
Support PharmPK by using the
Copyright 1995-2011 David W. A. Bourne (firstname.lastname@example.org)